GlassScriptPhysician profile
Claire J Byrd
NPI 1134653116
$2,430.99
in general payments reported to CMS, 2019-2025
19 companies · $671 in 2025
The $671 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $71.27 · 2022: $249 · 2023: $651 · 2024: $788 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,041 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,041.42 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $463.22 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $418.43 | 2022-2025 | |
| Astellas Pharma US INC | $357.96 | 2023-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $246.98 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $161.12 | 2022-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $161.11 | 2022-2025 | Shingrix, Bexsero, Arexvy |
| Pfizer INC. | $125.90 | 2022-2025 | |
| Exact Sciences Corporation | $114.30 | 2023-2025 | Cologuard Collection Kit |
| Genzyme Corporation | $71.27 | 2021 | |
| Merck Sharp & Dohme LLC | $61.31 | 2023-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Sanofi Pasteur INC. | $54.69 | 2023-2025 | |
| Becton, Dickinson and Company | $40.43 | 2022-2025 | Bd Onclarity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.66 | 2022-2023 | Synjardy, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $30.99 | 2023 | Trintellix |
| Idorsia Pharmaceuticals US INC | $24.87 | 2022-2023 | Quviviq |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $17.37 | 2022 | |
| Supernus Pharmaceuticals, INC. | $17.14 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.93 | 2023 | |
| Amgen INC. | $15.31 | 2024 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claire Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.